BCRX analyst estimates
BioCryst (BCRX) analyst ratings, the average price target and its range, and every firm's latest call.
BCRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 10, 2026 | RBC Capital | BioCryst downgraded to Sector Perform from Outperform at RBC Capital | $11.00 |
| Jul 7, 2026 | RBC Capital | BioCryst price target raised to $14 from $13 at RBC Capital | $14.00 |
| Jun 30, 2026 | Jefferies | BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies | $17.00 |
| Jun 30, 2026 | Cantor Fitzgerald | BioCryst price target raised to $29 from $27 at Cantor Fitzgerald | $29.00 |
| Nov 5, 2025 | JMP Securities | BioCryst price target lowered to $25 from $27 at Citizens JMP | $25.00 |
| Nov 4, 2025 | Barclays | BioCryst price target lowered to $9 from $11 at Barclays | $9.00 |
| Oct 14, 2025 | Jefferies | BioCryst price target raised to $15 from $14 at Jefferies | $15.00 |
| Oct 14, 2025 | RBC Capital | BioCryst weakness presents 'compelling' buying opportunity, says RBC | $15.00 |
| Oct 1, 2025 | Evercore ISI | BioCryst downgraded to In Line from Outperform at Evercore ISI | $8.00 |
| Aug 6, 2024 | Barclays | BioCryst price target raised to $7 from $6 at Barclays | $7.00 |
| Aug 5, 2024 | Jefferies | BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies | $11.00 |
| Nov 2, 2022 | Evercore ISI | UPDATE: Evercore ISI Upgrades BioCryst Pharma (BCRX) to Outperform | $16.00 |
| Aug 23, 2022 | Barclays | BioCryst (BCRX) Stock: $14 Target And Equal-Weight Rating | $14.00 |
| Jan 10, 2022 | Cowen & Co. | BioCryst Pharma (BCRX) PT Raised to $25 at Cowen on Orladeyo Sales Data | $25.00 |
| Nov 3, 2021 | Cantor Fitzgerald | Analysts Offer Insights on Healthcare Companies: BioCryst (NASDAQ: BCRX) and Penumbra (NYSE: PEN) | $21.00 |
- 8 firms rate BCRX: 5 buy, 3 hold, 0 sell.
- The average price target is $19.00 from 3 analysts, from $11.00 to $29.00.
Updated 2026-11-03 00:00 UTC